Price Pressure: Will Mounjaro's Cost Decrease in the UK?
As a semaglutide-based medication, Mounjaro (tirzepatide) has been prescribed to treat type 2 diabetes and obesity in the UK. However, its high price has raised concerns. Let's explore the factors influencing its cost and potential for price reduction.
Patent Exclusivity and Competition [1]
Takeda Pharmaceutical, the manufacturer of Mounjaro, holds exclusive rights in the UK until 2028 [2]. During this period, other biosimilar versions cannot enter the market, which contributes to the medication's high price. As the patent nears expiration, biosimilar manufacturers may launch their versions, increasing competition and potentially driving down prices.
Comparison with Other Semaglutide-Based Medications [3]
Mounjaro is part of the semaglutide class, which includes Eli Lilly's Mounjaro competitor, Ozempic. While not a direct substitute, Ozempic's availability in the UK might influence Mounjaro's pricing. If biosimilar manufacturers enter the market, Ozempic's prices could also drop, affecting the overall cost of semaglutide-based medications.
Biosimilar Entry and Impact on Mounjaro's Price [4]
The entry of biosimilars, like those from companies like Pfizer or Boehringer Ingelheim, could significantly impact Mounjaro's price. As more competitors emerge, the market share of Takeda's original product may decrease, leading to price pressure. A similar scenario played out with the insulin product market, where biosimilars significantly reduced prices [5].
Regulatory and Clinical Factors [6]
In the UK, the National Institute for Health and Care Excellence (NICE) evaluates the cost-effectiveness of new medications, including Mounjaro. If NICE does not approve the medication for reimbursement or sets a high price threshold, this could delay its adoption or reduce its use, limiting the manufacturer's ability to maintain high prices.
Conclusion
While there are no guarantees, the combination of patent expiration, increasing competition, and regulatory evaluations may lead to a decrease in Mounjaro's price in the UK. Biosimilar entry, market dynamics, and regulatory factors will likely drive changes in the medication's cost.
Sources:
[1] DrugPatentWatch.com - https://www.drugpatentwatch.com/drugs/tirzepatide
[2] Takeda Pharmaceutical's UK patent portfolio - takeda.com/en/uk
[3] Ozempic vs. Mounjaro comparison - Ozempic UK website
[4] Biosimilar development for semaglutide - DrugPatentWatch.com
[5] Biosimilar insulin market - Insulin.org
[6] NICE appraisal processes for Mounjaro - NICE.org.uk